NCT00211471View on ClinicalTrials.gov

Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).

PHASE2TerminatedINTERVENTIONAL
0
Timeline

Start Date

March 31, 2002

Study Completion Date

May 31, 2007

Conditions
Severe Diabetic RetinopathyCentral Retinal Vein OcclusionChronic InflammationInfectious Diseases
Interventions
DRUG

anecortave acetate

Trial Locations (1)

10021

Manhattan Eye, Ear & Throat Hospital, New York

Sponsors

Collaborators (1)

Alcon Research
All Listed Sponsors
collaborator

Alcon Research

INDUSTRY

lead

Manhattan Eye, Ear & Throat Hospital

OTHER